Kahri J, Groop P H, Elliott T, Viberti G, Taskinen M R
Third Department of Medicine, University of Helsinki, Finland.
Diabetes Care. 1994 May;17(5):412-9. doi: 10.2337/diacare.17.5.412.
To study the distribution of high-density lipoprotein (HDL) subclasses in insulin-dependent diabetes mellitus (IDDM) patients with nephropathy and factors involved in the regulation of HDL, including plasma cholesteryl ester transfer protein (CETP) and postheparin plasma lipoprotein lipase (LPL) and hepatic lipase (HL) activities.
Participants included 52 microalbuminuric IDDM patients (with a urinary albumin excretion rate [UAER] of 20-200 micrograms/min), 37 macroalbuminuric IDDM patients (UAER > 200 micrograms/min), and 64 normoalbuminuric IDDM patients (UAER < 20 micrograms/min). Groups were matched for age, body mass index, duration of diabetes, and glycemic control (HbA1).
Median concentrations of HDL and HDL2 cholesterol were 11.6 (P = 0.01) and 22.7% (P = 0.01) less in microalbuminuric patients and 5.1 and 15.5% less in macroalbuminuric patients compared with normoalbuminuric patients. No significant differences were observed in the concentrations of apoA-I, apoA-II (apolipoprotein) or LpA-I or LpA-I:A-II (lipoprotein) particles between the groups. HDL cholesterol: apoA-I+apoA-II ratio was significantly lower in micro- (19.7 +/- 4.2 (+/- SD); P < 0.01) and macroalbuminuric patients (20.0 +/- 3.7, P < 0.05) than in normoalbuminuric patients (22.1 +/- 4.4). Postheparin plasma LPL:HL ratio was lower in microalbuminuric patients compared with normoalbuminuric patients (1.65 vs. 1.05 [median], P < 0.01). Plasma CETP activity was higher in the macroalbuminuric patients than in micro- (P < 0.05) and normoalbuminuric patients (P < 0.05) but did not correlate with HDL, HDL2, or HDL3 cholesterol. LPL:HL ratio correlated positively with HDL cholesterol (r = 0.372, P < 0.001), HDL2 cholesterol (r = 0.413, P < 0.001) and with LpA-I particles (r = 0.355, P < 0.001) but not with LpA-I:A-II particles (r = -0.065, NS).
IDDM patients with micro- and macroalbuminuria show only trivial changes in concentrations of different HDL parameters, which cannot explain the excess risk of coronary heart disease in these patients. Data also indicate that elevation of CETP activity in IDDM patients with nephropathy is probably not responsible for the lowering of HDL cholesterol.
研究胰岛素依赖型糖尿病(IDDM)肾病患者高密度脂蛋白(HDL)亚类的分布以及参与HDL调节的因素,包括血浆胆固醇酯转运蛋白(CETP)、肝素后血浆脂蛋白脂肪酶(LPL)和肝脂肪酶(HL)活性。
参与者包括52例微量白蛋白尿IDDM患者(尿白蛋白排泄率[UAER]为20 - 200微克/分钟)、37例大量白蛋白尿IDDM患者(UAER > 200微克/分钟)和64例正常白蛋白尿IDDM患者(UAER < 20微克/分钟)。各组在年龄、体重指数、糖尿病病程和血糖控制(糖化血红蛋白A1[HbA1])方面进行了匹配。
与正常白蛋白尿患者相比,微量白蛋白尿患者的HDL和HDL2胆固醇中位数浓度分别低11.6%(P = 0.01)和22.7%(P = 0.01),大量白蛋白尿患者分别低5.1%和15.5%。各组之间载脂蛋白A-I(apoA-I)、载脂蛋白A-II(apoA-II)或脂蛋白A-I(LpA-I)或脂蛋白A-I:A-II(LpA-I:A-II)颗粒的浓度无显著差异。HDL胆固醇与apoA-I + apoA-II的比值在微量白蛋白尿患者(19.7 ± 4.2[±标准差];P < 0.01)和大量白蛋白尿患者(20.0 ± 3.7,P < 0.05)中显著低于正常白蛋白尿患者(22.1 ± 4.4)。与正常白蛋白尿患者相比,微量白蛋白尿患者的肝素后血浆LPL:HL比值较低(中位数分别为1.65对1.05,P < 0.01)。大量白蛋白尿患者的血浆CETP活性高于微量白蛋白尿患者(P < 0.05)和正常白蛋白尿患者(P < 0.05),但与HDL、HDL2或HDL3胆固醇无关。LPL:HL比值与HDL胆固醇(r = 0.372,P < 0.001)、HDL2胆固醇(r = 0.413,P < 0.001)以及LpA-I颗粒(r = 0.355,P < 0.001)呈正相关,但与LpA-I:A-II颗粒(r = -0.065,无显著性差异)无关。
微量和大量白蛋白尿的IDDM患者不同HDL参数浓度仅有微小变化,这无法解释这些患者冠心病风险增加的原因。数据还表明,IDDM肾病患者中CETP活性升高可能并非导致HDL胆固醇降低的原因。